Tumor antigens recognized by T lymphocytes - PubMed (original) (raw)
Review
Tumor antigens recognized by T lymphocytes
T Boon et al. Annu Rev Immunol. 1994.
Abstract
Transplantation experiments have demonstrated that most mouse tumors express antigens that can constitute targets for rejection responses mediated by syngeneic T lymphocytes. For human tumors, autologous cultures mixing tumor cells and blood lymphocytes or tumor-infiltrating lymphocytes have produced CD8+ and CD4+ cytolytic T cell (CTL) clones that recognize tumor cells specifically. Attempts to identify the target antigens by biochemical fractionation of tumor cells up to now have failed, with the important exception of the identification of underglycosylated mucins present on breast and pancreatic carcinomas. Gene transfection approaches have proved more successful. A gene family named MAGE codes for antigens recognized by autologous CTL on a melanoma tumor. These genes are not expressed in normal tissues except for testis. They are expressed in many tumors of several histological types. Differentiation antigens coded by genes such as tyrosinase are also recognized on human melanoma by autologous CTL. The identification of human tumor rejection antigens opens new possibilities for systematic approaches to the specific immune therapy of cancer.
Similar articles
- Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P. Valmori D, et al. Cancer Res. 1997 Feb 15;57(4):735-41. Cancer Res. 1997. PMID: 9044853 - Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Chaux P, et al. J Immunol. 1999 Sep 1;163(5):2928-36. J Immunol. 1999. PMID: 10453041 - A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. van der Bruggen P, et al. Eur J Immunol. 1994 Dec;24(12):3038-43. doi: 10.1002/eji.1830241218. Eur J Immunol. 1994. PMID: 7805731 - Tumor antigens recognized by T lymphocytes.
Van den Eynde BJ, Boon T. Van den Eynde BJ, et al. Int J Clin Lab Res. 1997;27(2):81-6. doi: 10.1007/BF02912440. Int J Clin Lab Res. 1997. PMID: 9266277 Review. - [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
Gaugler B, Olive D. Gaugler B, et al. Pathol Biol (Paris). 1998 Dec;46(10):771-8. Pathol Biol (Paris). 1998. PMID: 9922993 Review. French.
Cited by
- Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.
Chen YL, Chang MC, Chen CA, Lin HW, Cheng WF, Chien CL. Chen YL, et al. PLoS One. 2012;7(10):e47190. doi: 10.1371/journal.pone.0047190. Epub 2012 Oct 17. PLoS One. 2012. PMID: 23082146 Free PMC article. - Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma.
Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, Akahori T, Tanaka T, Migita K, Ito M, Nakajima Y. Enomoto K, et al. Clin Exp Immunol. 2012 May;168(2):186-91. doi: 10.1111/j.1365-2249.2012.04565.x. Clin Exp Immunol. 2012. PMID: 22471279 Free PMC article. - Management of Immune Checkpoint Inhibitor Toxicities.
Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A, Gross-Goupil M, Daste A. Durrechou Q, et al. Cancer Manag Res. 2020 Sep 28;12:9139-9158. doi: 10.2147/CMAR.S218756. eCollection 2020. Cancer Manag Res. 2020. PMID: 33061607 Free PMC article. Review. - Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas.
Kim Y, Bae JM, Li G, Cho NY, Kang GH. Kim Y, et al. PLoS One. 2015 Apr 15;10(4):e0122183. doi: 10.1371/journal.pone.0122183. eCollection 2015. PLoS One. 2015. PMID: 25875774 Free PMC article. - Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY, Wang RF. Wang HY, et al. Adv Immunol. 2012;114:151-76. doi: 10.1016/B978-0-12-396548-6.00006-8. Adv Immunol. 2012. PMID: 22449781 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials